drugset / Trial / NCT03635827

Xenon Inhalation for Treatment of Posttraumatic Stress Disorder

NCT03635827

Phase 2/3 Unknown 190 enrolled Nobilis Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with PTSD.

Timeline

Start
2021-06
Primary completion
2021-06
Completion
2021-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Xenon Other / unclassified 10 unknown Inhaled